Chen Xinqi, Wang Mingjie, Yan Zhaoli
Department of Endocrinology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China.
Diabetol Metab Syndr. 2025 Mar 6;17(1):84. doi: 10.1186/s13098-025-01655-2.
Diabetes mellitus is associated with systemic damage across multiple organ systems, and an increasing number of patients are presenting with diabetic kidney disease as its initial manifestation. The onset and progression of diabetic nephropathy is closely associated with podocyte injury.
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors, which can significantly reduce glucose levels as well as protecting against kidney damage, are therefore widely used for the clinical treatment of patients with diabetic kidney disease. An increasing body of research has revealed that the renal protective effect of SGLT2 inhibitors is primarily derived from their enhancement of podocyte autophagy and their inhibition of inflammation and podocyte apoptosis. Multiple signaling pathways are involved in these processes.
A deeper exploration of the renal protective effects of SGLT2 inhibitors and the underlying mechanisms will provide more solid theoretical support for their application in the prevention and treatment of diabetic kidney disease.
糖尿病与多个器官系统的全身性损害相关，越来越多的患者以糖尿病肾病作为其首发表现。糖尿病肾病的发生和进展与足细胞损伤密切相关。
2型钠-葡萄糖协同转运蛋白（SGLT2）抑制剂可显著降低血糖水平并预防肾脏损伤，因此被广泛用于糖尿病肾病患者的临床治疗。越来越多的研究表明，SGLT2抑制剂的肾脏保护作用主要源于其增强足细胞自噬以及抑制炎症和足细胞凋亡。这些过程涉及多个信号通路。
对SGLT2抑制剂的肾脏保护作用及其潜在机制进行更深入的探索，将为其在糖尿病肾病防治中的应用提供更坚实的理论支持。
